Dongyangguang Pharmaceutical’s first anti-Nipah virus “lifesaving drug” has entered clinical trials, achieving a 100% mortality protection rate in animal prevention.
February 25, 2026
Source: drugdu
28
On February 24, Dongyangguang Pharmaceutical (06887) issued an announcement stating that the Center for Drug Evaluation of the National Medical Products Administration of China has formally accepted the company's application for clinical trials of HEC-648 injection, a monoclonal antibody new drug targeting the Nipah virus G protein. Phase I clinical research is expected to be officially launched in 2026.
Nipah virus is a highly lethal single-stranded negative-sense RNA virus, with a mortality rate ranging from 40% to 75%. Currently, Nipah virus is classified as a biosafety level 4 virus, and there are no approved targeted treatments or vaccines available.。
HEC-648 injection is a fully human monoclonal antibody targeting the Nipah virus G protein, a research achievement of the Wuhan Institute of Virology, Chinese Academy of Sciences. In animal model experiments, this drug demonstrated a 100% preventative mortality protection rate and over 80% therapeutic mortality protection rate, making it the first and only specific drug developed in China for Nipah virus to enter the clinical registration stage.
https://finance.eastmoney.com/a/202602243652832049.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA February 25, 2026
- Dashi Pharmaceuticals licenses its migraine medication to NewCo in the United States. February 25, 2026
- United Laboratories subsidiary, UBT251 injection (a Class 1 innovative drug), achieved near-20% weight loss in Phase II clinical trials February 25, 2026
- 34 million patients no longer rely on imported drugs February 25, 2026
- How far can GLP-1 go in the weight loss race? February 25, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
